CRISPR Therapeutics AG (NASDAQ:CRSP) traded at $63.93 at last check on Wednesday, May 27, making a downturn move of -3.63% on its previous day’s price.
Looking at the stock we see that its previous close was $66.34 and the beta (5Y monthly) reads 2.25 with the day’s price range being $59.90 – 66.59. The company has a 12-month trailing PE ratio of 83.46. In terms of its 52-week price range, CRSP has a high of $74 and a low of $32.3. The company’s stock has gained about 16.24% over that past 30 days.
There have been 7 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the CRSP stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 17 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 4 have rated the CRISPR Therapeutics AG (CRSP) stock as a Hold, while 11 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas 2 suggests the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the CRSP stock currently stands at 0, and the current price level is 10.47% off its SMA20 and 28.15% from its 50-day simple moving average. The RSI (14) is pointing at 60.99 while the volatility over the past week is 6.62% and jumps to 7.28% over the past one month. The beta value is 2.26, while the average true range (ATR) is currently pointing at 4.07. The average price target for the stock over the next 12 months is $73.82, with the estimates having a low of $31 and a high of $104. These price ends are -51.51% and +62.68% off the current price level respectively, although investors could be excited at the prospect of a +25.14% if the CRSP share price touches on the median price of $80.
Let’s briefly compare CRISPR (CRSP) stock to its peers. We find that today’s price change of -3.63% and +74.1% over the past 12 months for CRSP competes that of Amgen Inc (AMGN), which has seen its stock price rise 1.08% in the latest trading session and is +33.14% over the last one year. Another of its peers Gilead Sciences Inc (GILD) has climbed 2.35% today, and is +17.09% up over the past year, while Vertex Pharmaceutic (VRTX) is also down -3.63% yet its price remains in the green at 74.1% over the same period. Amgen has a P/E ratio of 17.61 compared to CRISPR’s 84.79 and Gilead’s 19.25. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 2.21% and 1.48%, respectively, in early deals.
Coming back to CRISPR Therapeutics AG (NASDAQ:CRSP), we note that the average 3-month trading volume was 967.89 Million, while that of the preceding 10-day period stands at 1.16 Million. Current shares outstanding are 61.02 Million.
According to data from Thomson Reuters, insiders hold 20.94% of the company’s shares while institutions hold 55.73%. The data shows that short shares as of April 29, 2020, stood at 4.02 Million at a short ratio of 4.92. This represents a 6.58% Short interest in Shares outstanding on April 29, 2020. Shares short rose in April from the previous month at 3.27 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +4.97% up in year-to-date price movement.